Neutropenia and G-CSF in lymphoproliferative diseases.

about

Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen.Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia.

P2860

Q33414659-6E7338B9-976E-40C3-83B0-9B1D2EE92F5A Q50042993-D9265695-70FA-4037-A22A-0EF2C68AB2A4

P2860

Neutropenia and G-CSF in lymphoproliferative diseases.

Item

http://www.wikidata.org/entity/Q36828921

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Neutropenia and G-CSF in lymphoproliferative diseases.

@en

type

Item

label

Neutropenia and G-CSF in lymphoproliferative diseases.

@en

prefLabel

Neutropenia and G-CSF in lymphoproliferative diseases.

@en

P1476

Neutropenia and G-CSF in lymphoproliferative diseases.

@en

P2093

Angelo Vacca

http://www.w3.org/2001/XMLSchema#string

Antonia Reale

http://www.w3.org/2001/XMLSchema#string

Franco Dammacco

http://www.w3.org/2001/XMLSchema#string

Michele Moschetta

http://www.w3.org/2001/XMLSchema#string

P2860

Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.

American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.

Risk models for predicting chemotherapy-induced neutropenia.

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

P304

131-137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1179/1607845412Y.0000000049

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Roberto Ria

P577

2012-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234141519

http://www.w3.org/2001/XMLSchema#string

P698

23321273

http://www.w3.org/2001/XMLSchema#string

P932

3648783

http://www.w3.org/2001/XMLSchema#string

Neutropenia and G-CSF in lymphoproliferative diseases.

about

P2860

P2860

Neutropenia and G-CSF in lymphoproliferative diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932